BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte (PCVX)VaxcyteEarnings

VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages Studied VAX-31 Adult Indication: Company Expects to Report

Related news

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-05-06 20:05 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

VXRTVaxart2026-08-06 20:05 EST

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

VXRTVaxart2026-05-07 20:05 EST

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

GSKGSK plc2025-04-30 07:00 EST

GSK makes strong start to 2025 with growth in sales, profits and earnings

GSKGSK plc2026-01-07 07:00 EST

GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-11-04 21:05 EST

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-10-09 20:05 EST

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

PCVXVaxcyte2026-10-07 02:49 EST

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 20:28 EST

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 10:00 EST

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

Stock data

Close
61.92 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States